Pancreatic Intraepithelial Neoplasia: A New Nomenclature and Classification System for Pancreatic Duct Lesions
By R. Hruban, N. Adsay, J. Albores–Saavedra, Carolyn Compton, Elizabeth S. Garrett, S. Goodman, S. Kern, D. Klimstra, G. Klöppel, D. Longnecker and 2 more. American Journal of Surgical Pathology, 2001
1,145 citations recorded by the source corpus.
View Paper: https://www.semanticscholar.org/paper/ed06c6b54e6b7c397f066a2b6e88871ae7a99e5b
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Oncology
In Surgery
Citations in the corpus
- Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. (2005, background): “…of disease pathogenesis has been gleaned from static analyses of resected pancreatic tumor specimens giving rise to histologic (Brat et al., 1998; Hruban et al., 2001a; Klimstra and Longnecker, 1994) and molecular (Hruban et al., 2000; Hruban et al., 2001b) frameworks for disease progression.”
- The Pancreatic Cancer Microbiome Promotes Oncogenesis by Induction of Innate and Adaptive Immune Suppression (2018, neutral): “PanINs were graded according to established criteria (33): In PanIN I ducts, the normal cuboidal pancreatic epithelial cells transition to columnar architecture (PanIN Ia) and gain polyploid morphology (PanIN Ib).”
- An Illustrated Consensus on the Classification of Pancreatic Intraepithelial Neoplasia and Intraductal Papillary Mucinous Neoplasms (2004, methodology): “Although the previous classification system used size as the sole criterion to distinguish between IPMNs and PanINs, no specific guidelines were given for measuring the size of an involved duct (ie duct diameter versus length of involved segment).(27) 3.”
- Genetics and biology of pancreatic ductal adenocarcinoma. (2006, background): “2; Klimstra and Longnecker 1994; Moskaluk et al. 1997; Heinmoller et al. 2000; Hruban et al. 2000b, 2001; Wilentz et al. 2000; Yamano et al. 2000; Luttges et al. 2001; Maitra et al. 2003).”
- Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma. (2003, background): “pioneered by Jackson et al. (2001) and/or a conditional Ink4a/Arf knockout allele in the germline.”